Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of GLPG3970
NCT04708184Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Jan 2021
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GLPG3970 in psoriasis, ulcerative colitis (UC) and rheumatoid arthritis (RA) (3 arms), sponsored by Galapagos NV. Primary endpoints: Maximum observed plasma concentration at Day 4, Area under the plasma concentration-time curve from time zero to infinity at Day 4 and 1 more. Started Jan 2021; status: completed.
02
Drugs
GLPG3970
03
Conditions
psoriasisulcerative colitis (UC)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04708184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708184.